This research investigates chemoresistance mechanisms in colorectal cancer, highlighting the role of extracellular vesicles circular RNA as a potential biomarker.
Colorectal cancer (CRC) is a common and deadly malignancy worldwide, causing high morbidity and mortality rates. Chemoresistance continues to be the major barrier to the effective treatment of CRC. Circular RNA (circRNA), a recently identified class of non-coding RNA, has become an emerging focus in CRC research due to its abundant presence and stability in extracellular vesicles (EVs). The circRNA of EVs (EVs-circRNA) is closely associated with CRC progression and plays a pivotal role in chemoresistance mechanisms. This paper investigates the circRNA mechanism underlying different chemoresistance scenarios in CRC and explores the dual role of EVs-circRNA in mediating chemotherapy resistance. Furthermore, EVs-circRNA, a non-invasive biomarker for liquid biopsies, holds significant promise in clinical applications, ranging from early CRC diagnosis to monitoring disease progression and assessing prognosis. These studies provide a new perspective for uncovering CRC pathogenesis and lay the foundation for precision therapy and personalized treatment strategies for CRC. In the future, therapeutic strategies targeting EVs-circRNAs are anticipated to revolutionize CRC treatment, leading to improved therapeutic outcomes and enhanced quality of life for patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: